{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Expanded Access Program for belantamab mafodotin in Patients with Relapsed\/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody","item":"https:\/\/www.regionalcancercare.org\/trials\/expanded-access-program-for-belantamab-mafodotin-in-patients-with-relapsed-refractory-multiple-myeloma-who-are-refractory-to-a-proteasome-inhibitor-and-an-immunomodulatory-agent-and-an-anti-cd38-ant\/#breadcrumbitem"}]}